Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
13/08/2026 21:06
BRIEF-4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million Aug 13 (Reuters) - 4D Molecular Therapeutics Q2 operating expenses USD 80.806 million.
- Q2 operating income USD -77.025 million vs. IBES estimate USD -74.3 million
- Q2 basic EPS USD -1.04
- Q2 revenue USD 3.781 million vs. IBES estimate USD 3.1 million
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings